
|Videos|August 13, 2021
Aurion Biotech: Treating endothelial disease with one donor
Author(s)David Hutton, Alex Delaney-Gesing
Edward Holland, MD, discusses Aurion Biotech's investigation of an injectable technique where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease.
Advertisement
Edward Holland, MD, chief medical advisor for Aurion Biotech, discusses the company's investigation of injectable endothelial cells, where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease as well as other forms of corneal edema.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
DSLT for glaucoma and ocular hypertension: Real-world outcomes in 218 eyes
2
ARPA-H funds tear-duct biosensor system for dry eye, systemic disease
3
Memento Medicines launches with $93 million Series A to advance Tie2-activating bispecific for retinal disease
4
First patient dosed in phase 3 pivotal cohort of LIGHTHOUSE trial evaluating ATSN-201 for X-linked retinoschisis
5























